Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: Description of a clinical protocol

BioFactors

Volumn 18, Issue 1-4, 2003, Pages 125-127

  Silver, Marc A ^a,b   Langsjoen, Peter H ^a   Szabo, Szabolcs ^a   Patil, Harish ^a   Zelinger, Allan ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b ADVOCATE CHRIST MEDICAL CENTER   (United States)

Author keywords

Co Enzyme Q10; Diastolic dysfunction; Statin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVALONIC ACID; UBIDECARENONE;

CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECELERATION; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG SAFETY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE CELL; HEART VENTRICLE FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; M MODE ECHOCARDIOGRAPHY; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RELAXATION TIME; STATISTICAL ANALYSIS; STUDENT T TEST; VOLUMETRY;

EID: 0348049891     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520180214     Document Type: Conference Paper

References (15)

1. L. Goldman, P. Coxson and M.G. Hunink et al., The relative influence of secondary versus primary prevention using NCEP Adult Treatment Panel II guidelines, J Am Coll Cardiol 34 (3) (Sept. 1999), 768-776.
2. 10 lowering effect by HMG-CoA reductase inhibitors: double blind placebo controlled study, J Clin Pharmacol 33 (3) (Mar. 1993), 226-229.
3. 10 during treatment with HMG-CoA reductase inhibitors, Mol Aspects Med 18 (1997), S137-144.
4. 10 preserves plasma ubiqinone levels inpatients treated with 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitors, Int J Clin Lab Res 24 (3) (1994), 171-176.
5. 10 function and pharmacological reactions, in: Biomedical and Clinical Aspects of Coenzyme Q, K. Folkers and Y. Yamamura, eds, (Vol. 5), Amsterdam: Elsevier, 1986, pp. 3-14.
6. 10, Proc Natl Acad Sci USA 82 (1985), 901-904.
7. 10, Proc Natl Acad Sci USA 82 (1985), 4240-4244.
8. 10 levels in, Proc Natl Acad Sci USA 87 (1990), 8931-8934.
9. G. De Pinieux, P. Chariot and M. Ammi-Said et al., Lipid lowering drugs and mitochondrial function? effects of HMG-CoA reductase inhibitors on serum Ubiquinone and blood lactate/pyruvate ratio, Br J Clin Pharmacol 42 (3) (Sept. 1993), 333-337.
10. M. DeLogeril, P. Salen, L. Bontems and P. Belichard et al., Effects of lipid lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients, J Cardiovasc Pharmacol 33 (1999), 473-478.
11. Heart Disease, A Text book of Cardiovascular disease, Editors Braunwald; Fifth edition, Chapter 12, 384-385.
12. W.H. Gaash, Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction, JAMA 274 (16) (1994), 1276-1280.
13. C.S. Rihal, R.A. Nishimura, L.K. Hatle, K.R. Bailey and A.J. Tajik, Systolic and Diastolic dysfunction in patients with clinical diagnosis of dilated Cardiomyopathy, Relation to Symptoms and Prognosis, Circulation 90 (6) 1994), 2772-2779.
14. C.S. Rihal, R.A. Nishimura, L.K. Hatle, K.R. Bailey and A.J. Tajik, Systolic and Diastolic dysfunction in patients with clinical diagnosis of dilated Cardiomyopathy, December, 1994, or diastolic dysfunction. JAMA (16) (1994), 1276-1280.
15. P.D. Thompson, P. Clarkson and R.H. Karas, Statin-associated myopathy, JAMA 289 (13) (2003), 1681-1690.